TY - JOUR
T1 - Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan
AU - Goto, Tatsunori
AU - Tanaka, Takashi
AU - Sawa, Masashi
AU - Ueda, Yasunori
AU - Ago, Hiroatsu
AU - Chiba, Shigeru
AU - Kanamori, Heiwa
AU - Nishikawa, Akinori
AU - Nougawa, Masaharu
AU - Ohashi, Kazuteru
AU - Okumura, Hirokazu
AU - Tanimoto, Mitsune
AU - Fukuda, Takahiro
AU - Kawashima, Naomi
AU - Kato, Tomonori
AU - Okada, Kazuya
AU - Nagafuji, Koji
AU - Okamoto, Shin ichiro
AU - Atsuta, Yoshiko
AU - Hino, Masayuki
AU - Tanaka, Junji
AU - Miyamura, Koichi
N1 - Publisher Copyright:
© 2017, The Japanese Society of Hematology.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The Japan Marrow Donor Program (JMDP) has facilitated unrelated peripheral blood stem cell transplantation (URPBSCT) since 2010. We conducted a prospective multicenter observational study to evaluate the feasibility of such transplantation. Between 2011 and 2014, 51 patients underwent URPBSCT from 8/8 allele-matched donors for hematological malignancies. The median age of the patients was 50 years; 21 had high-risk disease. Myeloablative conditioning regimens were used in 31 patients, and tacrolimus based graft-versus-host disease (GVHD) prophylaxis was used for all patients. The cumulative rate of engraftment was 96%. With a median follow-up period of 610 days for survivors, 100-day and 1-year overall survival rates were 86 and 59%, respectively. The cumulative incidence of non-relapse mortality and relapse at 1 year were 14 and 35%, respectively. The incidence of grade II to IV acute GVHD at 100 days and extensive type of chronic GVHD at 1 year were 25 and 32%, respectively. The probability of overall survival was comparable with that of bone marrow transplantation from HLA matched-unrelated donors in Japan, although the incidence of chronic GVHD was higher. Further follow-up with more patients is clearly warranted to establish the optimal use of URPBSCT together with the approaches of minimizing chronic GVHD.
AB - The Japan Marrow Donor Program (JMDP) has facilitated unrelated peripheral blood stem cell transplantation (URPBSCT) since 2010. We conducted a prospective multicenter observational study to evaluate the feasibility of such transplantation. Between 2011 and 2014, 51 patients underwent URPBSCT from 8/8 allele-matched donors for hematological malignancies. The median age of the patients was 50 years; 21 had high-risk disease. Myeloablative conditioning regimens were used in 31 patients, and tacrolimus based graft-versus-host disease (GVHD) prophylaxis was used for all patients. The cumulative rate of engraftment was 96%. With a median follow-up period of 610 days for survivors, 100-day and 1-year overall survival rates were 86 and 59%, respectively. The cumulative incidence of non-relapse mortality and relapse at 1 year were 14 and 35%, respectively. The incidence of grade II to IV acute GVHD at 100 days and extensive type of chronic GVHD at 1 year were 25 and 32%, respectively. The probability of overall survival was comparable with that of bone marrow transplantation from HLA matched-unrelated donors in Japan, although the incidence of chronic GVHD was higher. Further follow-up with more patients is clearly warranted to establish the optimal use of URPBSCT together with the approaches of minimizing chronic GVHD.
KW - Allogeneic hematopoietic cell transplantation
KW - Peripheral blood stem cell
KW - Unrelated donor
UR - http://www.scopus.com/inward/record.url?scp=85031420580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031420580&partnerID=8YFLogxK
U2 - 10.1007/s12185-017-2341-y
DO - 10.1007/s12185-017-2341-y
M3 - Article
C2 - 29027623
AN - SCOPUS:85031420580
SN - 0925-5710
VL - 107
SP - 211
EP - 221
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 2
ER -